COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma
Name:
37665297.pdf
Size:
1.474Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
van Akkooi, A. C.Hauschild, A.
Long, G. V.
Mandala, M.
Kicinski, M.
Govaerts, A. S.
Klauck, I.
Ouali, M.
Lorigan, Paul C
Eggermont, A. M.
Affiliation
Melanoma Institute Australia, the University of Sydney & Royal Prince Alfred Hospital, 40 Rocklands Road Wollstonecraft, Sydney 2065, NSW, AustraliaIssue Date
2023
Metadata
Show full item recordAbstract
Stage IIB/IIC melanoma has a high risk of recurrence after surgical resection. While, for decades, surgery was the only option for high-risk stage II disease in most countries, adjuvant therapies now exist. Anti-programmed cell death protein 1 (PD-1) antibodies significantly improve recurrence-free survival versus placebo in patients with fully resected stage IIB/IIC melanoma. Combined BRAF MEK inhibitor therapy showed benefits in high-risk stage III and advanced disease; however, its role in patients with fully resected stage BRAF-mutated IIB/IIC melanoma is still unknown. Here we describe the rationale and design of the ongoing randomized, placebo-controlled COLUMBUS-AD trial, the first study of a BRAF-MEK inhibitor combination therapy (encorafenib + binimetinib) in patients with BRAF V600-mutated stage IIB/IIC melanoma.Citation
van Akkooi AC, Hauschild A, Long GV, Mandala M, Kicinski M, Govaerts AS, et al. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma. Future oncology (London, England). 2023 Sep 4. PubMed PMID: 37665297. Epub 2023/09/04. eng.Journal
Future OncologyDOI
10.2217/fon-2023-0414PubMed ID
37665297Additional Links
https://doi.org/10.2217/fon-2023-0414Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.2217/fon-2023-0414